Organization (Industry)
Renovo (United Kingdom)
ClinicalTrials.gov lists Renovo (United Kingdom) as lead sponsor of 30 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Renovo (United Kingdom): 30 lead-sponsored trials and 1 legal-entity registration.
Disease areas (7)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cicatrix | 25 |
| Fibrosis | 25 |
| Keloid | 3 |
| Varicose Veins | 2 |
| Burns | 1 |
Showing 5 of 7 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2010 | 1 |
| 2009 | 4 |
| 2008 | 4 |
| 2007 | 2 |
| 2006 | 5 |
| 2005 | 2 |
| 2004 | 4 |
| 2003 | 3 |
| 2002 | 3 |
| 2001 | 2 |
Recruitment duration, a model prediction: none of the 30 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Estradiol | 1 |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Plastic and reconstructive surgery | 2 |
| Journal of immunology (Baltimore, Md. : 1950) | 1 |
| Lancet (London, England) | 1 |
| The British journal of surgery | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 19 | 0 | 2011-05-24 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Various reprocessed products: PROVISION, Reprocessed Smith and Nephew Arthroscopic Shavers, STERILE EO; PROVISION Reprocessed Depy Mitek Ablation Electrodes, VAPR COOLPULSE 90 deg; PROVISION Reprocessed Smith and Nephew Trocars/ Cannulas (Class I); PROVISION Reprocessed Conmed/ Linvatec Suture Retrievers/ Passers C6387 See updated product list attached for details. | Class II | 2021-01-19 |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Icon Plc | Uses vendor | 1 |
Latest dated events (50)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2021-01-19 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2011-05-24 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2011-03-08 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2011-02-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2010-06-01 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 50 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| OTOR | Trial sponsor | Named in trial inclusion criteria |
| OTOR | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.